Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/an-overview-of-the-taxus-express-paclitaxel-eluting-stent-clinical-qaMRNOiuRQ
References (28)
-
S. Marx, A. Marks (2001)
Bench to bedside: the development of rapamycin and its application to stent restenosis.Circulation, 104 8
-
Neil Weissman, J. Koglin, David Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, M. Kutcher, S. Wong, Warren Strickland, M. Mooney, M. Russell, Stephen Ellis, Gregg Stone (2005)
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.Journal of the American College of Cardiology, 45 8
-
R. Moreno, C. Fernández, R. Hernández, F. Alfonso, D. Angiolillo, M. Sabaté, J. Escaned, C. Bañuelos, A. Fernández-Ortiz, C. Macaya (2005)
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.Journal of the American College of Cardiology, 45 6
-
K. Dawkins, G. Stone, A. Colombo, E. Grube, S. Ellis, J. Popma, P. Serruys, Peter Lam, J. Koglin, M. Russell (2006)
Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2 1
-
E. Grube, S. Silber, K. Hauptmann, L. Buellesfeld, R. Mueller, V. Lim, U. Gerckens, M. Russell (2005)
Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I).The American journal of cardiology, 96 1
-
Antti Virkamaki, K. Ueki, C. Kahn (1999)
Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.The Journal of clinical investigation, 103 7
-
Stone Stone, Ellis Ellis, Cox Cox (2005)
Three‐year safety and efficacy of the polymer‐based paclitaxel‐eluting TAXUS stent: The TAXUS‐IV trialCirculation, 112
-
K. Tanabe, P. Serruys, E. Grube, P. Smits, Guido Selbach, W. Giessen, M. Staberock, P. Feyter, R. Müller, E. Regar, M. Degertekin, J. Ligthart, C. Disco, B. Backx, M. Russell (2003)
TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer FormulationCirculation: Journal of the American Heart Association, 107
-
Colombo Colombo (2006)
TAXUS II 3‐year clinical results: Durability of the benefit of polymer‐based, paclitaxel‐eluting stents in the treatment of de novo coronary artery lesionsAm J Cardiol, 96
-
Blagosklonny Blagosklonny, Darzynkiewicz Darzynkiewicz, Halicka Halicka (2004)
Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cellsCell Cycle, 3
-
Rowinsky Rowinsky, Donehower Donehower (1995)
Paclitaxel (taxol)N Engl J Med, 332
-
R. Schwartz, N. Chronos, R. Virmani (2004)
Preclinical restenosis models and drug-eluting stents: still important, still much to learn.Journal of the American College of Cardiology, 44 7
-
W. Lau, P. Gurbel, P. Watkins, Charlene Neer, Amy Hopp, D. Carville, K. Guyer, A. Tait, E. Bates (2004)
Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel ResistanceCirculation: Journal of the American Heart Association, 109
-
Y. Mitsuuchi, S. Johnson, M. Selvakumaran, Stephen Williams, T. Hamilton, J. Testa (2000)
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.Cancer research, 60 19
-
K. Dawkins, E. Grube, G. Guagliumi, A. Banning, K. Żmudka, A. Colombo, L. Thuesen, Karl Hauptman, J. Marco, W. Wijns, J. Popma, J. Koglin, M. Russell (2005)
Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical PracticeCirculation, 112
-
M. Morice, P. Serruys, J. Sousa, J. Fajadet, E.Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, F. Molnár, R. Falotico (2002)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.The New England journal of medicine, 346 23
-
Ellis Ellis, O'Shaughnessy O'Shaughnessy, Powers Powers (2005)
Twelve month clinical outcomes of the TAXUS V trial: Focus on late clinical benefits and multiple stentingAm J Cardiol, 96
-
G. Stone, S. Ellis, C. O'shaughnessy, Steven Martin, L. Satler, T. Mcgarry, M. Turco, D. Kereiakes, Lynne Kelley, J. Popma, M. Russell (2006)
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.JAMA, 295 11
-
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, J. Popma, M. Russell (2004)
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.The New England journal of medicine, 350 3
-
E. Grube, S. Silber, K. Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, M. Russell (2003)
TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary LesionsCirculation: Journal of the American Heart Association, 107
-
A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, D. Dudek, S. Fort, F. Schiele, K. Zmudka, G. Guagliumi, M. Russell (2003)
Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation: Journal of the American Heart Association, 108
-
J. Moses, M. Leon, J. Popma, P. Fitzgerald, D. Holmes, C. O'shaughnessy, R. Caputo, D. Kereiakes, David Williams, P. Teirstein, Judith Jaeger, R. Kuntz (2003)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.The New England journal of medicine, 349 14
-
P. Wenaweser, J. Dörffler-Melly, Katja Imboden, S. Windecker, M. Togni, B. Meier, A. Haeberli, O. Hess (2005)
CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy -
T. Wight (1995)
The extracellular matrix and atherosclerosisCurrent Opinion in Lipidology, 6
-
G. Stone, S. Ellis, L. Cannon, J. Mann, Joel Greenberg, D. Spriggs, C. O'shaughnessy, Samuel DeMaio, Patrick Hall, J. Popma, J. Koglin, Mary Russell (2005)
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.JAMA, 294 10
-
D. Roith, Y. Zick (2001)
Recent advances in our understanding of insulin action and insulin resistance.Diabetes care, 24 3
-
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, J. Popma, M. Russell (2004)
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV TrialCirculation: Journal of the American Heart Association, 109
-
Wenaweser Wenaweser, Dorffler‐Melly Dorffler‐Melly, Imboden Imboden (2005)
Stent thrombosis is associated with an impaired response to antiplatelet therapyJ Am Coll Cardiol, 45
- Publisher
- Wiley
- Copyright
- Copyright © 2006 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0896-4327
- eISSN
- 1540-8183
- DOI
- 10.1111/j.1540-8183.2006.00183.x
- pmid
- 17020567
- Publisher site
- See Article on Publisher Site
Abstract
Restenosis remains a problem following percutaneous coronary intervention in patients with coronary artery disease. Drug‐eluting stents (DES), which combine mechanical and pharmacologic properties, have been shown to prevent or reduce neointimal growth after deployment. This review describes the TAXUS paclitaxel‐eluting stent clinical trial expansion program (TAXUS® Express®, Boston Scientific, Natick, MA). This program comprises the largest data set of randomized controlled trials (RCTs) of DES to date, with over 6,200 patients enrolled since 2000. The program includes treatment of de novo lesions, as well as higher‐risk lesion and patient populations. In this review, we discuss the results from the TAXUS family of randomized clinical trials, and compare the findings with data from TAXUS registries. The data from the randomized clinical trials suggest that the paclitaxel‐eluting stent provides consistent and durable benefits across multiple lesion and patient types. Evidence from peri‐and postapproval registries, where patient populations are more heterogeneous than those eligible and included in the RCTs, corroborate these findings, with overall low rates of cardiac events, including reinterventions.
Journal
Journal of Interventional Cardiology – Wiley
Published: Oct 1, 2006